bioRxiv · 10.1101/156331
Polygenic hazard scores in preclinical Alzheimer’s disease
Abstract
Identifying asymptomatic older individuals at elevated risk for developing Alzheimers disease (AD) is of clinical importance. Among 1,081 asymptomatic older adults, a recently validated polygenic hazard score (PHS) significantly predicted time to AD dementia and steeper longitudinal cognitive decline, even after controlling for APOE {varepsilon}4 carrier status. Older individuals in the highest PHS percentiles showed the highest AD incidence rates. PHS predicted longitudinal clinical decline among older individuals with moderate to high CERAD (amyloid) and Braak (tau) scores at autopsy, even among APOE {varepsilon}4 non-carriers. Beyond APOE, PHS may help identify asymptomatic individuals at highest risk for developing Alzheimers neurodegeneration.
Source connections
Explore related subjects
Keep this discovery
Tan, C. H., Sugrue, L. P., Broce, I. J., Tong, E., Tan, J., Hess, C. P., Dillon, W. P., Bonham, L. W., Yokoyama, J. S., Rabinovici, G. D., Rosen, H. J., Miller, B. L., Hyman, B. T., Schellenberg, G. D., Besser, L. M., Kukull, W. A., Karch, C. M., Brewer, J. B., Kauppi, K., McEvoy, L. K., Andreassen, O. A., Dale, A. M., Fan, C. C., Desikan, R. S.. 2017-06-27. Polygenic hazard scores in preclinical Alzheimer’s disease. https://doi.org/10.1101/156331
Cite the original work for its findings. Save a collection to share your selection of sources.